Full-Time
Global Clinical Lead
Clinical Scientist
Posted on 10/31/2025
Telix Pharmaceuticals
1,001-5,000 employees
Develops targeted radiation diagnostics and therapies
No salary listed
Remote in Canada
Remote
 Biology & Biotech (2) |
|---|
| , |
- Medical degree (MD) or doctoral degree (PhD) in a relevant scientific discipline is required.
- Demonstrated experience in oncology or nuclear medicine is required, with a strong understanding of the clinical and scientific landscape.
- 5 years of industry experience in clinical development, with a proven track record of leading clinical programs through early-phase development. Experience in early-stage clinical trial design and execution is strongly preferred.
- Solid understanding of global clinical trial methodology, regulatory frameworks, and submission processes. Experience preparing and submitting regulatory documents (e.g., INDs, CTAs) and engaging with health authorities (e.g., FDA, EMA) is preferred.
- Demonstrated success in leading cross-functional teams and managing complex clinical development programs from concept through execution.
- Strong knowledge of clinical trial design, data interpretation, and the ability to translate scientific insights into strategic development plans.
- Willingness to travel domestically and internationally, as needed.
- Lead Clinical Strategy Development: Define and drive the clinical development plans for Fibroblast Activation Protein (FAP) imaging assets, ensuring alignment with Telix’s broader asset strategy and commercial objectives.
- Cross-Functional Collaboration: Partner closely with Global Program Heads, Regulatory Affairs, Medical Affairs, and Translational Medicine to ensure clinical trial objectives are integrated into the overall development strategy and reflect the needs of diverse stakeholders.
- Clinical Study Design and Execution: Oversee the development of clinical study plans from concept through to protocol finalization, ensuring scientific rigor and alignment with regulatory expectations, healthcare provider needs, patient advocacy perspectives, and market access requirements.
- Clinical Documentation Leadership: Lead the creation and review of essential clinical documentation—including informed consent forms, imaging charters, study manuals, and regulatory dossiers—in collaboration with medical writers and cross-functional teams.
- Regulatory and Scientific Contributions: Provide expert clinical input into key regulatory and scientific documents, including Investigator Brochures, IMPDs, DSURs, PSURs, SUSARs, Clinical Study Reports, and global regulatory submissions (e.g., INDs, BLAs, NDAs, MAAs).
- Data Integrity and Analysis: Lead the review, interpretation, and quality control of clinical data, including efficacy, safety, and imaging endpoints, to ensure data integrity and support decision-making across the development lifecycle.
- Stakeholder Communication: Prepare and deliver high-impact presentations, proposals, and reports for senior leadership, external partners, and strategic collaborators to communicate program progress and clinical insights.
- External Engagement and Thought Leadership: Cultivate relationships with Key Opinion Leaders (KOLs), organize advisory boards, and collaborate with subject matter experts, consultants, and vendors to inform clinical strategy and enhance program visibility.
- Experience in early-stage clinical trial design and execution is strongly preferred.
- Experience preparing and submitting regulatory documents (INDs, CTAs, and related submissions) and engaging with health authorities (FDA, EMA) is preferred.
- External engagement and thought leadership with KOLs, advisory boards, and consultants to inform clinical strategy and enhance program visibility is desirable.
- Inclusion and diversity mindset, creativity and innovation, commitment to excellence, results orientation, ethical behavior, adaptability, strong communication, collaboration, resilience, and continuous learning are desirable personal capabilities.
Telix Pharmaceuticals develops and commercializes diagnostic and therapeutic products that use targeted radiation to diagnose and treat cancer and rare diseases. Its pipeline covers urologic oncology (prostate and kidney cancers), neuro-oncology (glioma), musculoskeletal oncology (sarcoma), and bone marrow conditioning. The treatments work by delivering targeted radiation to diseased tissues, enabling more precise decisions for treatment and allowing for personalized therapy. The company differentiates itself through a global, robust supply chain and a focus on integrating diagnostic and therapeutic options to address unmet medical needs, along with strong commitments to patient care, ethical practices, and environmental responsibility. Telix’s goal is to improve quality of life and outcomes for patients by providing targeted, clinically meaningful diagnostic and therapeutic solutions that support better treatment decisions and personalized care.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Melbourne, Australia
Founded
2015
Simplify's Take
What believers are saying
- Regeneron $4.3B deal provides $40M upfront and 50/50 profit share on eight solid tumor programs.
- $600M convertible notes fund pipeline acceleration without immediate equity dilution until 2031.
- FDA accepted Pixclara NDA resubmission with September 12, 2026 PDUFA for glioma imaging revenue.
What critics are saying
- Regeneron deprioritizes programs, forcing Telix to co-fund alone or forfeit $535M milestones.
- Pixclara rejection by September 2026 erodes credibility after prior FDA CRLs on CMC issues.
- $1.15B debt matures 2031 if revenue growth stalls below 22.7% annually to $1.2B by 2029.
What makes Telix Pharmaceuticals unique
- Telix targets LAT1 with TLX101, achieving 12.4-month median OS in Ipax-Linz phase 2 glioma trial.
- Theranostic strategy pairs Illuccix imaging with TLX591 therapy for PSMA-positive prostate cancer.
- Acquired ImaginAb's small antibody platform for alpha-emitting DLL3 and αvβ6 radiotherapies.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Annual Performance Bonus
Equity-Based Incentive Program
Paid Vacation
Paid Wellness Days
Hybrid Work Options
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 15%1 year growth
↑ 0%2 year growth
↑ 0%Telix Pharmaceuticals' shares rose 13.8% following its partnership announcement with Regeneron Pharmaceuticals to develop radiopharmaceutical therapies for solid tumours. The collaboration includes a $40 million upfront payment and combines Regeneron's antibody platforms with Telix's manufacturing and distribution network. The agreement offers Telix flexibility to either co-fund programmes and share global profits or receive milestone payments plus royalties. The deal begins with four programmes under a cost and profit-sharing model. The FDA recently accepted Telix's NDA resubmission for TLX101-Px, setting an 11 September 2026 review date. However, investors face risks from pricing pressure in PSMA imaging and execution challenges. Telix's narrative projects $1.2 billion revenue and $111.3 million earnings by 2029, requiring 22.7% annual revenue growth.
Telix Pharmaceuticals' bankers offered shares in the company to fund managers on Tuesday evening as part of hedging activity linked to a $US550 million ($775 million) convertible bond raising. The move represents standard practice for underwriters managing convertible bond offerings, who typically hedge their exposure by offering shares to institutional investors.
Telix partners with Regeneron on radiopharmaceutical therapies in USD 2.1b potential deal. April 13, 2026 Australia-based Telix Pharmaceuticals Ltd (ASX: TLX, Nasdaq: TLX) and US firm Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced a strategic collaboration to jointly develop and commercialize next-generation antibody-based radiopharmaceutical therapies across multiple solid tumor indications. The agreement pairs Telix's radiopharmaceutical development platform and global manufacturing infrastructure with Regeneron's antibody discovery technologies, including its VelocImmune and VelociSuite platforms, to generate a pipeline of radiolabeled biologics. Specific tumor targets have not been disclosed. Deal specifics. Under the deal terms, Telix will receive an upfront payment of USD 40 million from Regeneron for access to its radiopharmaceutical manufacturing platform across four initial therapeutic programs. Should Telix elect to opt out of co-funding on any individual program, it becomes eligible to receive up to USD 535 million in development and commercial milestone payments per program, plus low double-digit royalties on net sales, with an aggregate milestone ceiling of USD 2.1 billion across all programs. Where Telix remains in the co-funding model, the two companies will share equally in global development costs and commercialization profits on a 50/50 basis, with Telix retaining the option to co-promote certain products. The collaboration covers four initial therapeutic programs, with Regeneron holding the option to expand to four additional programs subject to further upfront payments. The parties will also jointly develop radio-diagnostic assets to support patient selection and treatment response monitoring, with Telix leading commercialization of those diagnostics and Regeneron receiving a defined percentage of profits. The exact percentage was not disclosed. The structure gives Telix a per-program election right at a defined decision point: co-fund and share in global profits equally, or opt out and revert to a milestone-plus-royalty economics model. This optionality allows Telix to allocate capital selectively depending on program progression and resource constraints, while preserving upside participation across the portfolio. The agreement is global in scope, with no geographic carve-outs or territorial allocations disclosed. No equity investment by either party in the other was announced in connection with the transaction. The drug programs will combine Regeneron's antibody targeting components, drawn from its portfolio of antibodies generated through VelocImmune mice, with Telix's radiolabeling and manufacturing capabilities. The modality class is antibody-based radiopharmaceutical therapy, in which a tumor-antigen-binding antibody serves as the targeting vehicle for a therapeutic radionuclide payload. The collaboration also encompasses potential bispecific antibody formats, given Regeneron's established expertise in that area. Regeneron noted in its public commentary that it intends to explore these agents as monotherapy and in rational combination with its immunotherapy platform, citing lung cancer as one area of interest where its PD-1 inhibitor is already in use. The specific antigens, antibody names, and radionuclide payloads for the collaboration programs have not been publicly identified. The theranostic component of the agreement, pairing matched diagnostic and therapeutic agents using the same antibody targeting vector, supports patient stratification and dosimetry assessment ahead of and during treatment. Telix will lead commercialization of the diagnostic assets developed under the collaboration. Strategic implications. Regeneron's entry into radiopharmaceutical oncology drug development marks a modality expansion for a company whose oncology portfolio has been anchored in antibody-based immunotherapy. The company indicated it views targeted radiopharmaceuticals as a frontier in oncology and has framed the collaboration as an opportunity to apply its antibody discovery engine to a delivery modality it has not previously pursued commercially. For Telix, the arrangement provides validation of its radiopharmaceutical manufacturing infrastructure as a platform asset capable of attracting large-scale co-development partnerships. Telix's existing commercial radiopharmaceutical portfolio includes Illuccix kit for the preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC injection (also known as 68Ga-PSMA-11 injection), approved by the US FDA as a prostate cancer imaging agent. In addition, the firm announced on April 9, 2026, that the US FDA has accepted an NDA filing for TLX101-Px (Pixclara, Floretyrosine F 18 or 18F-FET), an investigational PET agent for the imaging of glioma (brain cancer). Your email address will not be published. Required fields are marked *
Telix and regeneron sign $4.3bn deal to co-develop radiopharmaceutical therapies. Srivani Venna
Telix and Regeneron to co-develop radiopharmaceutical therapies. The partnership reflects a focus on precision oncology, seeking to enhance patient selection and assess treatment responses. Telix and Regeneron Pharmaceuticals have entered a partnership for the development and commercialisation of new radiopharmaceutical therapies. This collaboration aims to integrate Telix's expertise in radiopharmaceutical platforms, global manufacturing and supply chain infrastructure with Regeneron's biologics knowledge, particularly in bispecific antibody discovery. Regeneron will initially provide Telix with an upfront cash payment of $40m for access to the latter's radiopharmaceutical manufacturing platform for four therapeutic initiatives. There is an option for Regeneron to expand to another four programmes, which would involve further upfront payments. Both companies will equally share the costs and potential profits worldwide, with Telix optionally co-promoting certain products. If Telix chooses to step back from funding a specific programme, it could gain up to $535m in developmental and commercial milestones, in addition to low double-digit royalties on subsequent net sales. Regeneron oncology and antibody technology research senior vice-president John Lin said: "At Regeneron, Pharmaceutical Technology follow the science to determine the best therapeutic approach for each disease, continuously expanding its toolbox of treatment modalities - from monoclonal and bispecific antibodies to cell therapies and beyond. "Targeted radiopharmaceuticals represent a rapidly emerging frontier in oncology and an exciting opportunity to bring new treatment options to patients in need." The collaboration will include several solid tumour targets from Regeneron's antibody portfolio, benefiting from its VelocImmune mice technology. It reflects a joint focus on precision oncology, seeking to enhance patient selection and assess treatment responses through new radio-diagnostics. The companies also plan to develop diagnostic assets, where Telix will spearhead the commercialisation efforts, and Regeneron will receive a predetermined share of the profits. In December 2025, Regeneron teamed up with Tessera Therapeutics to develop and commercialise Tessera's rare disease in vivo gene writing programme, TSRA-196. Give your business an edge with its leading industry insights.